New
First patient enrolled in AVITA Therapeutic’s study in Miami earlier this week. The prospective study is evaluating the RECELL system for repigmentation of patients with stable vitiligo, meaning they have not had new vitiligo lesions or lesions that have expanded for at least one year.
AVITA’s technology creates an autologous suspension from a piece of the patient's own normal skin in under 30 minutes, to spray pigment-producing cells onto vitiligo lesion.
The company is about to begin two multi-center clinical trials in the USA (details 1 and details 2)
For more information, please contact: Elizabeth Kirshner at 661-367-9180 or ekirshner@avitamedical.com
FAQOther Questions
- What tests should be done?
A well-trained dermatologist should be able to diagnose vitiligo and distinguish it from contact leukoderma or more than twenty other conditions with similar skin appearance bas...
- How can I cure vitiligo?
There is no cure for vitiligo, but there are a number of effective treatment options that can be discussed with your GP or dermatologist. The aim of treatment is to stop new pat...
- What are risks of oral and topical corticosteroids?
Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.